Bard acquires Liberator Medical for $181M
According to a company statement, Bard will pay $3.35 per share for Liberator, and the bid is a 36% premium over Liberator’s 90-day average closing price through yesterday.
Boston Scientific closes Bard EP acquisition
Healthcare business intelligence: Boston Scientific (BSX) closed on its acquisition of C.R. Bard‘s Bard EP Nov. 1. According to a company statement, the addition of Bard’s advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices will help BSX address the $2.5 billion EP market, which is growing by as much as 10 percent yearly. […]
C.R. Bard buys Lutonix’s drug-coated balloon catheter for PAD for $225M
C.R. Bard Inc. will acquire the Maple Grove, Minnesota startup Lutonix Inc. for its novel drug-coated balloon catheter for treatment of peripheral artery disease. New Jersey-based medical device firm Bard announced Tuesday it would pay $225 million up front and an additional $100 million if the U.S. Food and Drug Administration grants pre-market approval for […]
Davol lawsuits to largely end with $184 million settlement
C.R. Bard Inc. (NYSE:BCR) will pay $184 million to settle most of the lawsuits against subsidiary Davol Inc.’s hernia repair products. Through late last year, more than 2,700 plaintiffs had filed suit in either federal or state courts pursuing product-liability claims for personal injuries, with most of those cases since transferred to the U.S. District […]
C.R. Bard FDA recall focuses on Davol’s XenMatrix
The XenMatrix FDA recall says the hernia and abdominal wall repair product has high levels of endotoxins. Davol is a subsidiary of C.R. Bard.
Women’s health company Hologic sees stocks jump after patent decision
Medical device company Hologic will continue with a patent infringement case. The original lawsuit alleged that SenoRx violated Hologic's patents for its MammoSite brachytherapy balloon catheter device. The system delivers radiation to the cavity left from the removal of cancerous breast tissue during lumpectomy.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Johnson & Johnson stent maker, Bard lay off workers
Johnson & Johnson's Cordis Corp. subsidiary, which makes the Cypher drug-eluting stent, confirmed that it will lay off some of its sales force and merge two sales operations in response to sliding Cypher sales. Also, C.R. Bard Inc. is cutting 200 jobs at a Queensbury, N.Y., plant.
C.R. Bard sees double-digit gains in Q2
Vascular and specialty surgical businesses post double-digit gains during the second quarter at C.R. Bard, as the company beats Wall Street estimates with $1.39 EPS. A strong dollar was just enough to bulk up second-quarter results at C.R. Bard Inc. (NYSE:BCR) as the surgical, vascular and oncology technology company out-muscled Wall Street expectations. The Murray […]
C.R. Bard acquires SenoRx for $200 million
C.R. Bard Inc. acquires SenoRx Inc. for $200 million, or $11 per share. C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO). The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share. C.R. Bard made the purchase at a 14 percent premium over SenoRx’s May […]
C.R. Bard’s R & D work fuels earnings increase
C.R. Bard Inc. (NYSE:BCR) posted first-quarter sales of $650.8 million, up 9.1 percent compared with $596.4 million during the same period last year. Net income for the Murray Hill, N.J.-based medical device maker rose 7.5 percent to $120.9 million, or $1.24 per diluted share, compared with $112.5 million, or $1.10 per diluted share, during Q1 […]
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Medtronic, Boston Scientific battle small firms for peripheral vascular market
Medical device companies agree the fast-growing peripheral vascular (PV) market is the place to be. The question is how are they going to get there? Devices that open clogged arteries below the waist are growing 10 percent to 12 percent a year, more than twice the growth rate of coronary products. Doctors have been generally […]
FDA issues warning about fake versions of C.R. Bard surgical mesh
The Food & Drug Administration is warning healthcare providers to be on the lookout for fake surgical mesh products that ape C.R. Bard’s (NYSE:BCR) Davol Inc. brand, saying hospitals and surgical centers — not to mention patients with surgical mesh implants — should be especially vigilant. The federal watchdog agency said four sizes of the […]